Readers will discover a company announcement outlining commercial strategy, product expansion plans, and efforts to broaden patient access to a simpler wearable mealtime insulin option.
Key Takeaways
- Company closed a $100 million Series E financing round
- Better than 85% of claims are covered as a pharmacy benefit
- Nearly 90% of patients reported improved adherence and better glycemic outcomes